CJC-1295 without DAC side effects and risks

Reported side effects

• Flushing and injection reactions: Reported in no DAC/ipamorelin threads; no denominator or verified product identity., moderate (source)
• Disturbed sleep or vivid dreams: Conflicting user reports with ipamorelin; no clinical event rate., mild (source)
• Racing heart: One thread includes a heart rate report up to 130 beats/min with the combination; cause is unverified., serious. Persistent racing heart, chest pain or fainting needs urgent care. (source)
• Blood sugar changes, swelling or joint pain: Related tesamorelin can cause these effects. Modified GRF 1 29 risks and rates are unknown., moderate (source)
• Allergic reaction or contaminated-injection infection: Unapproved injectable product risk; no modified GRF specific incidence estimate., serious (source)

Stop and get help if

• Trouble breathing, throat or face swelling, widespread hives, or collapse: Stop using it and call emergency services now.
• Chest pain, fainting, severe breathlessness, or a sustained racing heart: Stop exposure and seek emergency care now.
• Severe headache with vision change, vomiting, or new weakness: Get emergency care now; do not assume this is normal flushing.
• Rapid swelling or weight gain with shortness of breath: Seek urgent care now for possible fluid overload or heart problems.
• Hot spreading injection-site redness, severe pain, pus, or fever: Stop injections and get urgent same-day care; fever or rapidly worsening illness needs emergency care.
• Confusion, vomiting, marked thirst or urination, or low sugar that does not improve: Check blood sugar if available and seek urgent care; severe confusion or unconsciousness needs emergency services.

Who should avoid it

• pregnant: CJC pregnancy safety is unknown. Stop use during pregnancy.
• breastfeeding: Milk transfer and infant effects are unknown; avoid exposing a nursing infant.
• tryingToConceive: Fertility and early-pregnancy effects are unknown. This is a precautionary screen.
• under18: No child safety study was found. Growth hormone stimulation can affect growth.
• activeCancer: Growth hormone can support cell growth. Avoid no-DAC CJC with active cancer, following related-drug precautions.
• cancerHistory: A prior cancer needs individual review; long-term recurrence risk with CJC is unknown.
• other: Excess growth hormone makes this unsuitable; pituitary disease needs specialist review.
• other: A serious allergy to this peptide or its vial ingredients means avoiding further use.
• diabetes: Growth hormone can raise blood sugar. Diabetes was excluded from the HIV study; no-DAC safety data are lacking.
• diabeticRetinopathy: Related tesamorelin guidance warns about worsening diabetic eye disease; no-DAC CJC risk is unknown.
• heartCondition: No-DAC cardiac effects are unmeasured; fast heart rate is reported in users taking it with ipamorelin.
• uncontrolledBloodPressure: Blood-pressure instability and GH-related fluid retention warrant review before further exposure.
• sleepApnea: Sleep apnea raises baseline cardiometabolic risk; new snoring or breathing pauses need assessment.
• kidneyDisease: No kidney dosing study was found. Kidney disease can also cause swelling and change hormone tests.
• liverDisease: No liver dosing study was found; liver disease can distort IGF-1 blood tests.
• surgeryPlanned: Tell the anesthesia team about peptide and other hormone use; no perioperative CJC safety study was found.
• testedAthlete: WADA prohibits GHRH analogues at all times, including CJC-1295.

Interactions

• Insulin: Related tesamorelin can raise blood sugar. No-DAC CJC effects on insulin needs are unknown; review readings with your clinician when use starts or stops.
• Sulfonylureas: No-DAC CJC interactions are unknown. These medicines can cause severe low blood sugar; review readings with your clinician when use changes.
• Other GH, GHRH or ghrelin-pathway drugs: Effects may add, raising IGF-1 or glucose and fluid-retention concerns. No CJC/ipamorelin combination trial was found.
• Glucocorticoid replacement: Tesamorelin's label warns growth hormone can lower cortisol and change steroid replacement needs. No-DAC CJC effects are unknown.
• Medicines affected by liver CYP enzymes: Tesamorelin's label warns growth hormone may change drug breakdown. No-DAC CJC interactions remain unknown.
• Anticoagulants: Blood thinners increase bleeding and bruising from needle punctures. A direct CJC drug interaction has not been demonstrated.

Product quality risks

• DAC and no-DAC names are confused. FDA considers them different active moieties with different safety and exposure profiles.
• FDA found missing impurity, aggregate and endotoxin data in reviewed certificates. A high purity percentage alone cannot show injection safety.
• A 2010 seized sample contained a 29-amino-acid peptide consistent with the short form sold as CJC-1295; it was not proof of DAC identity.
• A 2019 seizure study identified glycine-added modified GRF and other secretagogues. Seized material is not a representative market survey.
• Regulators warn unapproved peptide vials may have too much, too little or no stated ingredient, particles, microbes or endotoxin.